Molex Agrees to Acquire Vectura Group
Private Equity Firm Carlyle Group to Sell its Portfolio Company
Acquisition Expands Molex's Medical Device Solutions
Molex, a leading global manufacturer of electronic components and solutions, has entered into an agreement to acquire Vectura Group, a provider of drug delivery technologies and services, from the Carlyle Group, a global private equity firm. The transaction is expected to close in the first half of 2023, subject to customary closing conditions, including regulatory approvals.
Vectura Group is a leading provider of inhalation drug delivery technologies and services, with a focus on complex generics, including dry powder inhalers (DPIs) and metered-dose inhalers (MDIs). The company has a strong portfolio of products and services that address a range of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.
Molex is a leading global manufacturer of electronic components and solutions, with a focus on the automotive, industrial, and medical markets. The company has a strong portfolio of products and services that include connectors, cables, switches, sensors, and other electronic components.
The acquisition of Vectura Group will expand Molex's medical device solutions portfolio and provide the company with access to new markets and technologies. Vectura Group's expertise in drug delivery technologies and services will complement Molex's existing capabilities in medical device manufacturing, and the combined company will be well-positioned to provide innovative and cost-effective solutions to meet the needs of patients and healthcare providers.
The Carlyle Group acquired Vectura Group in 2015, and under Carlyle's ownership, the company has grown its business through a combination of organic growth and acquisitions. Carlyle has a long history of investing in the healthcare sector, and the sale of Vectura Group to Molex is a testament to the firm's ability to identify and invest in high-growth companies.
Molex is a privately held company, and the terms of the transaction were not disclosed. The acquisition of Vectura Group is expected to be accretive to Molex's earnings per share.
Comments